| Treatment |
n |
Cmax (ng/mL) |
Tmax (h) |
t1/2 (h) |
AUC (ng•h/mL) |
Cl/F (L/h/kg) |
| Venlafaxine ER 150 mg Postprandial and Fasting |
16 |
166.4
77.0-246.8 |
7.9
6.0-10.0 |
12.2
8.0-19.0 |
4503
2535-6634 |
0.46
0.35-0.74 |
| Desvenlafaxine |
|
|
|
|
|
|
| 150 mg Postprandial |
6 |
203.5
118.7-346.0 |
4.5
2.0-10.0 |
9.1
8.1-11.8 |
4838
3344-6358 |
0.41
0.26-0.64 |
| 225 mg Postprandial |
6 |
421.0
292.2-609.3 |
6.6
4.0-16.0 |
11.1
8.4-14.6 |
10202
5950-14622 |
0.31
0.26-0.42 |
| 300 mg Postprandial |
6 |
444.9
393.7-486.8 |
7.1
2.0-28.0 |
10.3
7.2-12.0 |
14258
10760-17819 |
0.29
0.20-0.42 |
| 450 mg Postprandial |
6 |
807.8
562.8-984.9 |
4.9
4.0-6.0 |
10.1
9.1-11.3 |
18278
14344-23824 |
0.35
0.29-0.43 |
| 600 mg Postprandial |
6 |
1084.3
884.0-1337.8 |
5.2
4.0-7.0 |
10.2
8.8-11.2 |
26098
19635-42078 |
0.32
0.20-0.39 |
| 750 mg Postprandial |
5b |
1868.5
1431.7-2346.0 |
5.8
4.0-8.0 |
9.9
8.8-10.4 |
41478
36269-50949 |
0.26
0.23-0.30 |
| 900 mg Postprandial |
4c |
1540.9
1080.9-1830.9 |
7.2
6.0-8.0 |
9.6
8.6-10.9 |
37758
27392-45854 |
0.31
0.23-0.48 |
| 750 mg Fasting |
6 |
1658.6
1225.0-2054.6 |
6.8
6.0-8.0 |
9.5
7.8-11.2 |
36349
28669-43664 |
0.28
0.23-0.39 |
| 1-Factor ANOVA of Log-Transformed Data (Desvenlafaxine Postprandial Data Only)d |
| Treatment |
|
0.015 |
0.667 |
0.408 |
0.063 |
0.144 |
ANOVA, analysis of variance; AUC, area under the plasma concentration-time curve; Cl/F, apparent oral-dose clearance; Cmax, peak drug concentration; ER, extended release; t1/2, terminal-phase elimination half-life; Tmax, time of peak concentration.
aData shown are geometric mean, minimum-maximum.
bExcluding 1 subject who vomited and exhibited very low plasma concentrations.
cExcluding 2 subjects who vomited and exhibited very low plasma concentrations.
dBefore statistical comparisons, Cmax and AUC were normalized to the lowest dose. |
